TAVR

Transcatheter aortic valve replacement (TAVR) is a key structural heart procedure that has rapidly expanded in the decade since it was first FDA cleared. TAVR has come a paradigm shift in how many aortic stenosis patients are treated, now making up more than 50% of U.S. aortic valve replacements. It is less invasive than open heart surgery and recovery times are greatly reduced. TAVR can also be used in patients who otherwise are too high risk to undergo surgery. TAVR is referred to as transcatheter aortic valve implantation (TAVI) in many placed outside of the U.S. TAVR inspired the growing areas of transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

Treating younger patients with TAVR increases risk of death
Treating patients younger than 65 with TAVR is associated with certain risks for heart teams to consider. Fortunately, researchers found, care teams appear to be choosing patients wisely.
Cardiologist demand is on the rise—can hospitals keep up?
Demand for inpatient and outpatient cardiology services is expected to increase significantly in the next decade, putting hospitals and health systems in a position where they need to plan ahead or risk falling behind.
Self-expanding vs. balloon-expandable TAVR valves: How they compare after 5 years
SOLVE-TAVI focused on the long-term impact of selecting different second-generation transcatheter heart valves and anesthesia strategies for transfemoral TAVR procedures.
New data put a spotlight on troubling TAVR trends
Philippe Genereux, MD, principal investigator of the EARLY TAVR trial, noted that many patients with severe AS still go untreated.
Cardiologist behind EARLY TAVR explains how proactive treatment improves patient outcomes
Philippe Genereux, MD, principal investigator of the EARLY TAVR trial, discussed how a proactive treatment strategy for patients with asymptomatic AS can lead to better outcomes and improvements in quality of life.

How patient-specific simulations can improve TAVR care

Overall, the simulations inspired clinicians to change part of the treatment plan for 16 of 42 patients.

August 14, 2020

Outcomes ‘worse than expected’ when TAVR fails and surgery is required

The mortality rate was 17% for patients undergoing SAVR following a failed TAVR.

July 9, 2020

Outcomes continue to be favorable for low-risk TAVR patients receiving self-expanding valve

Low-risk transcatheter atortic valve replacement (TAVR) patients with aortic stenosis who receive the Evolut PRO continue to experience outcomes comparable to surgery.

June 24, 2020

Sapien 3 TAVR outcomes comparable to surgery after 5 years

Transcatheter aortic valve replacement (TAVR) with the Sapien 3 prosthesis achieved five-year clinical outcomes similar to surgical aortic valve replacement (SAVR).

June 24, 2020

Protamine administration during transcatheter aortic valve replacement (TAVR) is associated with a significant reduction in life-threatening and major bleeding complications.

June 23, 2020

Infective endocarditis after TAVR: 4 key findings from a new study of 7,000 patients

Infective endocarditis is a relatively rare complication of TAVR, but the infection can be fatal when it does strike.

June 19, 2020

Patient access to TAVR centers: 3 key takeaways from a new study

Do patients in the United States have sufficient access to TAVR centers?

June 10, 2020

Cardiologist sets sights on improving TAVR outcomes

A new study at the University of Cincinnati aims to find out why some TAVR patients experience clotting issues that can lead to substantial side effects.

June 4, 2020

TAVR

Treating younger patients with TAVR increases risk of death

Cardiologist demand is on the rise—can hospitals keep up?

Self-expanding vs. balloon-expandable TAVR valves: How they compare after 5 years

New data put a spotlight on troubling TAVR trends

Cardiologist behind EARLY TAVR explains how proactive treatment improves patient outcomes